Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has entered into an oncology research collaboration with AVEO Pharmaceuticals and Astellas Pharma.
Subscribe to our email newsletter
NCCN has received a research grant from AVEO and Astellas to evaluate the role of tivozanib in the treatment of solid tumors.
Tivozanib is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors.
NCCN vice president Diane Paul said grant support will fund clinical research in different types of solid tumors designed and carried out by investigators at NCCN Member Institutions.
AVEO chief medical officer William Slichenmyer said they collaborate with NCCN to further advance their understanding of tivozanib through clinical research.